OverviewSuggest Edit

Recro Gainesville (also known as Recro Pharma) is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The сompany is engaged in developing products for hospitals and ambulatory care settings that are developing non-opioid products for the treatment of serious acute pain. The сompany's lead product candidate is an injectable form of meloxicam.

TypePublic
Founded2006
HQMalvern, US
Websiterecrogainesville.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2019)213(-16%)
Job Openings8
Revenue (FY, 2019)$99.2 M(+29%)
Share Price (Oct 2020)$2.2
Cybersecurity ratingAMore

Key People/Management at Recro Gainesville

Gerri Henwood

Gerri Henwood

President & Chief Executive Officer
Wayne B. Weisman

Wayne B. Weisman

Chairman of the Board
Ryan D. Lake

Ryan D. Lake

CFO
Scott Rizzo

Scott Rizzo

Executive Vice President and General Manager
William L. Ashton

William L. Ashton

Director
Michael Berelowitz

Michael Berelowitz

Director
Show more

Recro Gainesville Office Locations

Recro Gainesville has offices in Malvern and Gainesville
Malvern, US (HQ)
490 Lapp Rd
Gainesville, US
1300 Gould Dr
Gainesville, US
988 Chestnut St SE
Show all (3)

Recro Gainesville Financials and Metrics

Recro Gainesville Revenue

Recro Gainesville's revenue was reported to be $99.22 m in FY, 2019
USD

Revenue (Q2, 2020)

15.5m

Gross profit (Q2, 2020)

3.9m

Gross profit margin (Q2, 2020), %

25%

Net income (Q2, 2020)

(6.0m)

EBIT (Q2, 2020)

(1.0m)

Market capitalization (16-Oct-2020)

50.8m

Closing stock price (16-Oct-2020)

2.2

Cash (30-Jun-2020)

22.8m

EV

144.6m
Recro Gainesville's current market capitalization is $50.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

52.0m69.3m71.8m77.3m99.2m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m43.2m51.0m

Gross profit

23.9m32.2m33.6m34.2m48.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m17.1m19.5m21.7m18.3m25.1m31.3m25.3m21.8m15.5m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m6.9m10.5m12.1m8.5m14.4m14.1m11.0m18.3m11.6m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m10.2m9.1m9.7m9.8m10.7m17.2m14.2m3.5m3.9m

Gross profit Margin, %

50%39%42%45%66%44%38%60%46%44%54%43%55%56%16%25%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

19.7m19.8m64.5m61.0m38.5m19.1m

Accounts Receivable

89.6k8.6m10.4m9.7m12.9m14.4m

Prepaid Expenses

3.3m3.9m2.7m

Inventories

9.0m1.1m9.8m10.7m15.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(16.1m)3.0m(30.2m)(50.1m)(79.7m)(18.6m)

Depreciation and Amortization

1.4k4.1m5.0m7.4m7.9m8.4m

Inventories

1.3m(325.0k)(1.1m)(860.0k)(4.4m)

Accounts Payable

1.1m2.2m8.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(26.0m)(12.5m)(25.2m)(38.4m)(2.0m)(4.8m)(9.1m)(7.7m)(13.7m)

Depreciation and Amortization

1.9m4.0m1.9m3.8m5.7m1.8m3.7m5.6m1.9m3.8m5.8m2.1m4.3m6.6m2.1m4.3m

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(1.1m)(189.0k)1.7m(343.0k)531.0k1.1m(2.2m)3.0m3.3m

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Recro Gainesville Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Gainesville Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Recro Gainesville Revenue Breakdown

Embed Graph

Recro Gainesville revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Recro Gainesville Online and Social Media Presence

Embed Graph

Recro Gainesville News and Updates

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Recro Pharma, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Jan. 2, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Recro Pharma, Inc. (NASDAQ: REPH). If you are a...

Recro Pharma Reports Third Quarter 2019 Financial Results

CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100 Million

Recro Pharma Reports First Quarter 2019 Financial Results

Company to Host Conference Call Today at 8:00 AM ET Company to Host Conference Call Today at 8:00 AM ET

Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

Management to Host Conference Call and Webcast Today at 4:30 p.m. ET Management to Host Conference Call and Webcast Today at 4:30 p.m. ET

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam

Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years
Show more

Recro Gainesville Blogs

Recro Pharma to Present at Upcoming Investor Conferences

MALVERN, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that Gerri Henwood, the Company’s President and Chief Execu…

Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019

Conference Call and Webcast Scheduled for Friday, May 10, 2019 at 8:00 a.m. ET MALVERN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conferen…

Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR® Capsules with Same Revenue Economics as the Original Agreement MALVERN, Pa., April 16, 2019 (GLOBE NEWSWIRE) -- Recro Ph…

Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain Abstract Among the Highest Scoring Presentations at the Meeting MALVERN, Pa., April 11, 2019 (GLOBE…

Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance

Implements Plan to Reduce Acute Care Segment Staff CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019 Expects to Become Cash Flow Breakeven During Q3; Cash Flow Positive Second Half of 2019 Plans to Seek Strategic Pa…

Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors

MALVERN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Directors. Mr. A…
Show more

Recro Gainesville Frequently Asked Questions

  • When was Recro Gainesville founded?

    Recro Gainesville was founded in 2006.

  • Who are Recro Gainesville key executives?

    Recro Gainesville's key executives are Gerri Henwood, Wayne B. Weisman and Ryan D. Lake.

  • How many employees does Recro Gainesville have?

    Recro Gainesville has 213 employees.

  • What is Recro Gainesville revenue?

    Latest Recro Gainesville annual revenue is $99.2 m.

  • What is Recro Gainesville revenue per employee?

    Latest Recro Gainesville revenue per employee is $465.8 k.

  • Who are Recro Gainesville competitors?

    Competitors of Recro Gainesville include CRBio, Amicus Therapeutics and Circassia.

  • Where is Recro Gainesville headquarters?

    Recro Gainesville headquarters is located at 490 Lapp Rd, Malvern.

  • Where are Recro Gainesville offices?

    Recro Gainesville has offices in Malvern and Gainesville.

  • How many offices does Recro Gainesville have?

    Recro Gainesville has 3 offices.